Stay up to date with our latest news and events.

Michael J. Fox Foundation

Michael J. Fox Foundation Announces Library of Available Recombinant DJ-1 Proteins in Collaboration with Proteos


The Michael J. Fox Foundation (MJFF) first goal is to propel breakthroughs that Parkinson's sufferers can immediately feel in their day to day lives. The foundation realizes the importance of protein reagents in many applications related to treating Parkinson's disease. MJFF has partnered with Proteos who provides them with the best quality reagents to support research of Parkinson's disease.

Tags: DJ-1, MJFF

Proteos to attend the 5th Annual Grand Challenges in Parkinson's Disease Scienti

Upcoming Event - Proteos to attend the 5th Annual Grand Challenges in Parkinson's Disease Scientific Symposium


Proteos will be attending the 5th annual Grand Challenges in Parkinson’s Disease scientific symposium at the Van Andel Research Institute in Grand Rapids, MI from September 26-27, 2016.  Please stop by our booth to learn more about Proteos.

Tags: Parkinson's, Van Andel Research Institute

New Alpha-synuclein Filament-specific Antibody


Now available from the MJFF Research Tools Program is a conformation-specific rabbit monoclonal antibody raised against filament alpha-synuclein, which recognizes both oligomeric and filamentous alpha-synuclein. This project was done in partnership with Proteos, Inc.; Abcam; and Aarhus University.

New Alpha-synuclein Proteins Available

Tags: Alpha-synuclein, MJFF

Commercial Launch of Human Alpha-synuclein Proteins


MJFF announced the commercial launch of human alpha-synuclein proteins including monomeric and filament versions, as well as protocols and specially formulated monomeric alpha-synuclein to generate pre-formed fibrils. This project was in partnership with Proteos, Inc., and the proteins were validated by the Jensen and Luk laboratories at Aarhus University and the University of Pennsylvania, respectively.

Tags: Alpha-synuclein, MJFF

Customize This